These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 16089166)

  • 1. [Problems raising from the control of biological products employed in medicine. Control of sera, vaccines, and biological products in France].
    Desbordes J
    Ann Ist Super Sanita; 1969; 5(3-4):218-81. PubMed ID: 16089166
    [No Abstract]   [Full Text] [Related]  

  • 2. [Laboratory for the control of serum vaccines and other biological products].
    M'Henni A
    Arch Inst Pasteur Tunis; 1997; 74(1-2):129-33. PubMed ID: 15945193
    [No Abstract]   [Full Text] [Related]  

  • 3. Who Expert Committee on Biological Standardization.
    World Health Organization
    World Health Organ Tech Rep Ser; 2004; 926():1-109. PubMed ID: 15918537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Principles of laboratory studies on sera and vaccines].
    Galazka A
    Pol Tyg Lek; 1968 Oct; 23(41):1575-9. PubMed ID: 5702420
    [No Abstract]   [Full Text] [Related]  

  • 5. Control of manufacture--the EC point of view.
    Meyer P
    Dev Biol Stand; 1992; 79():159-62. PubMed ID: 1286750
    [No Abstract]   [Full Text] [Related]  

  • 6. Control of manufacture--principles and purposes.
    Luff PR
    Dev Biol Stand; 1992; 79():155-8. PubMed ID: 1286749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing biological products and assessing comparability following manufacturing changes.
    Chirino AJ; Mire-Sluis A
    Nat Biotechnol; 2004 Nov; 22(11):1383-91. PubMed ID: 15529163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of product batches (before and after registration). The French approach.
    Vannier P
    Dev Biol Stand; 1992; 79():179-82. PubMed ID: 1286755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do natural compounds need specific drug development?
    Simon P; Verry M
    Prog Clin Biol Res; 1988; 280():407-21. PubMed ID: 3051029
    [No Abstract]   [Full Text] [Related]  

  • 10. Product development of probiotics as biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S128-32; discussion S144-51. PubMed ID: 18181718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WHO Expert Committee on Biological Standardization. Twentieth report.
    World Health Organ Tech Rep Ser; 1968; 384():1-100. PubMed ID: 4968938
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum supply: policies and controls operating in New Zealand.
    Shailer C; Corrin K
    Dev Biol Stand; 1999; 99():71-7. PubMed ID: 10404878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summary and conclusion. Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals.
    Castle P; Robertson JS
    Dev Biol Stand; 1999; 99():191-6. PubMed ID: 10404890
    [No Abstract]   [Full Text] [Related]  

  • 14. How do we assure the quality of biological medicines?
    Longstaff C; Whitton CM; Stebbings R; Gray E
    Drug Discov Today; 2009 Jan; 14(1-2):50-5. PubMed ID: 18951998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological standards and pharmacopoeias.
    Perkins FT
    Ann Ist Super Sanita; 1975; 11(3-4):322-32. PubMed ID: 1234734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-use manufacturing facilities.
    Garfinkle BD
    Dev Biol Stand; 1996; 88():131. PubMed ID: 9119124
    [No Abstract]   [Full Text] [Related]  

  • 17. The need for international surveillance of biologicals: distribution, use, and efficacy.
    Halter S; LaFontaine A
    Bull World Health Organ; 1977; 55 Suppl 2(Suppl 2):157-61. PubMed ID: 305308
    [No Abstract]   [Full Text] [Related]  

  • 18. FEDESA's point of view: quality, application to IVMPs (immunological veterinary medicinal products).
    Soulebot JP
    Dev Biol Stand; 1992; 79():201-11. PubMed ID: 1286759
    [No Abstract]   [Full Text] [Related]  

  • 19. Some problems associated with sterility testing in a commercial organization.
    Gasson AG
    Dev Biol Stand; 1974; 23():151-6. PubMed ID: 4459189
    [No Abstract]   [Full Text] [Related]  

  • 20. The Unites States Department of Agriculture Regulation of Veterinary Biological Products. The use of prelicensing evaluation and postlicensing monitoring to achieve regulatory compliance.
    Hill RE; Randall DC
    Qual Assur; 1995 Dec; 4(4):323-8. PubMed ID: 8890360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.